CagriSema (cagrilintide + semaglutide)
About 20% weight loss in a large trial. Not FDA-approved.
Grade A: Strong human proof
Big trials in people, and it worked.
The grade is for the use people talk about, not for every use. Filed under: Fat loss (GLP-1 family).
How it works
Pairs semaglutide with cagrilintide, a long-acting copy of amylin, a second fullness hormone.
How it was given in studies
Injection under the skin, in the trials. It is not approved.
This is what the studies did. It is not a how-to. Source: Trial record on ClinicalTrials.gov.
What studies saw
In a 68-week trial of 3,417 adults without diabetes, weight fell about 20% on the pair, against 3% on placebo. In 1,206 adults with type 2 diabetes it fell about 14%, against 3%.
The trade-off
Gut side effects hit about 80%, against 40% on placebo. Not FDA-approved when we checked on November 12, 2026, so anything sold now is unverified.
When it showed up, in studies
About 20% weight loss at 68 weeks.
Sources
Put this grade on your site
Copy the line below. The badge links back to this page, so readers can check the sources. It grades the compound in studies. It does not rate any product or seller.
<a href="https://www.workedinrats.com/compounds/cagrisema-cagrilintide-semaglutide"><img src="https://www.workedinrats.com/badge/cagrisema-cagrilintide-semaglutide.svg" alt="CagriSema (cagrilintide + semaglutide): grade A, strong human proof. Worked in Rats" width="300" height="72"></a>
Keep going
We show what studies found. We never tell you what to take. Doses vary by study. Check the sources and talk to a doctor.